Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8881037 | 0.98 | MAPT (0.61) | MAPTHTR2BALDH1A1PIM1RAB9A | |
| SCHEMBL3549550 | 0.85 | MAPT (0.63) | MAPTHTR2BALDH1A1RAB9AKDM4E | |
| SCHEMBL4539676 | 0.81 | MAPT (0.69) | MAPTHTR2BALDH1A1RAB9AKDM4E | |
| SCHEMBL21357610 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1PIM1RAB9A | |
| SCHEMBL10068466 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1PIM1RAB9A | |
| SCHEMBL6211632 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1RAB9AKDM4E | |
| SCHEMBL2225761 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1PIM1RAB9A | |
| SCHEMBL2439363 | 0.81 | CYP19A1 (0.66) | MAPTALDH1A1PIM1RAB9AKDM4E | |
| SCHEMBL6545742 | 0.81 | KDM4E (0.49) | MAPTHTR2BALDH1A1PIM1RAB9A | |
| SCHEMBL5461576 | 0.81 | SREBF2 (0.50) | MAPTALDH1A1PIM1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209488-A | Alkaloid barakacin derivative, synthesis thereof and application thereof in prevention and treatment of plant virus and germ diseases | 天津师范大学 | 2023-12-12 | — | — | CN | claimed |
| CN-111892532-A | Method for synthesizing 3-Cl propionyl substituted heterocyclic compound containing N by using micro-reaction device | 南京工业大学 | 2020-11-06 | — | — | CN | claimed |
| EP-2303021-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2018-12-19 | — | — | EP | claimed |
| CN-102137592-A | Compounds for the treatment of cancer | UNIV TENNESSEE RES FOUNDATION (US) | 2011-07-27 | — | — | CN | claimed |
| EP-4620949-A1 | ACKR3 MODULATORS FOR CARDIOVASCULAR OR ANTIPLATELET THERAPY | Eberhard Karls Universität Tübingen (Medizinische Fakultät) (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117209488-A | Alkaloid barakacin derivative, synthesis thereof and application thereof in prevention and treatment of plant virus and germ diseases | 天津师范大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-111253336-B | Compounds for the treatment of cancer | GTX公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-110680813-B | Use of naphthoquinone derivatives as IDO1 and/or TDO inhibitors | 北京大学 | 2023-03-10 | — | — | CN | disclosed |
| EP-0557834-A1 | Process for the preparation of heterocyclic aldehyds and ketones | BASF Aktiengesellschaft (DE) | 1993-09-01 | — | — | EP | disclosed |
| EP-0283035-B1 | BENZOXAZOLE DERIVATIVES AND PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-06 | — | — | EP | disclosed |
| US-4948900-A | INTERMEDIATES FOR DIABETES THERAPEUTIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4897393-A | ANTIDIABETIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1990-01-30 | — | — | US | disclosed |
| CN-88101542-A | Benzoxazole derivatives and process for preparing them | — | 1988-10-05 | — | — | CN | disclosed |
| EP-0283035-A1 | Benzoxazole derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| US-4380547-A | Dihydropyridine compounds which are substituted in the 4-position by imidazolyl or thiazolyl and their medicinal use | BAYER AKTIENGESELLSCHAFT (DE) | 1983-04-19 | — | — | US | disclosed |
| EP-0042089-A2 | 4-Heterocylic substituted dihydropyridines, processes for preparing them, their therapeutical use and their preparation | BAYER AG (DE) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MAPT 2614/4885HTR2B 4622/4885ALDH1A1 209/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAPT 2614/4885HTR2B 4622/4885ALDH1A1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.